BeiGene, Ltd.(BGNE) Stock Research - Grey Stern Research
Loading...

BeiGene, Ltd. (BGNE) Stock Analysis

$172.85 (1.06%)

BGNE Financial Performance


Use the table below to view BeiGene, Ltd.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $171.03 -
52 Week Low $126.97 -
52 Week High $245.74 -
Market Cap $17.9 Billion 1/17
Gross Margin 80% 11/17
Profit Margin -58% 9/17
EBITDA margin -57% 7/17
Q4 - 2023 Revenue $634.4 Million 3/17
Q4 - 2023 Earnings -$367.6 Million 17/17
Q4 - 2023 Free Cash Flow -$388.5 Million 15/17
Trailing 4 Quarters Revenue $2.5 Billion 3/17
Trailing 4 Quarters Earnings -$881.7 Million 16/17
Quarterly Earnings Growth 17% 10/17
Annual Earnings Growth 58% 5/17
Quarterly Revenue Growth 67% 10/17
Annual Revenue Growth 59% 7/17
Cash On Hand $3.2 Billion 3/17
Short Term Debt $710.3 Million 2/17
Long Term Debt $197.6 Million 8/17

BeiGene, Ltd. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare BeiGene, Ltd.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/17
PS 7.26 10/17
PB 5.00 11/17
PC 5.61 14/17
Liabilities to Equity 0.63 6/17
ROA -0.15 7/17
ROE -0.25 7/17
Current Ratio 2.60 11/17
Quick Ratio 1.43 10/17
Long Term Debt to Equity 0.06 9/17
Debt to Equity 0.26 6/17
Burn Rate 5.76 5/17
Cash to Cap 0.18 4/17
CCR 1.06 4/17
EV to EBITDA -43.33 12/17
EV to Revenue 6.34 11/17

Company Details

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

CEO: Mr. John V. Oyler

Website: https://www.beigene.com

Address: No.30 Science Park Road Beijing,

Exchange: NASDAQ Global Select

Industry: Biotechnology

BeiGene, Ltd. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to BeiGene, Ltd.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
ImmunoGen, Inc. IMGN $8.7 Billion
BioMarin Pharmaceutical Inc. BMRN $14.7 Billion
Ionis Pharmaceuticals, Inc. IONS $5.4 Billion
Incyte Corporation INCY $12.8 Billion
Arrowhead Pharmaceuticals, Inc. ARWR $3.1 Billion
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Blueprint Medicines Corporation BPMC $6.6 Billion
Apellis Pharmaceuticals, Inc. APLS $5.0 Billion
Krystal Biotech, Inc. KRYS $4.7 Billion
Ascendis Pharma A/S ASND $6.9 Billion
I-Mab IMAB $134.8 Million
Immunovant, Inc. IMVT $4.5 Billion
Legend Biotech Corporation LEGN $8.2 Billion
Vaxcyte, Inc. PCVX $8.1 Billion
Prometheus Biosciences, Inc. RXDX $9.6 Billion
Travere Therapeutics, Inc. TVTX $461.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BGNE Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 634.4 Million -$367.6 Million
Q3 2023 $ 781.3 Million $215.4 Million
Q2 2023 $ 595.3 Million -$381.1 Million
Q1 2023 $ 447.8 Million -$348.4 Million
Q4 2022 $ 380.1 Million -$445.3 Million
Q3 2022 $ 387.6 Million -$557.6 Million
Q2 2022 $ 341.6 Million -$571.4 Million
Q1 2022 $ 306.6 Million -$434.3 Million

View All

BGNE Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $3.2 Billion $5.8 Billion $930.2 Million $3.5 Billion
Q3 2023 $3.1 Billion $5.5 Billion $579.8 Million $3.8 Billion
Q2 2023 $3.4 Billion $5.7 Billion $677.8 Million $3.8 Billion
Q1 2023 $3.5 Billion $6.0 Billion $545.2 Million $4.2 Billion
Q4 2022 $3.9 Billion $6.4 Billion $891.1 Million $4.4 Billion
Q3 2022 $5,000 $50,000 $22,000 $2,000
Q2 2022 $4,000 $43,000 $10,000 $19,000
Q1 2022 $4.0 Million $43.0 Million $10.0 Million $19.0 Million

View All

BGNE Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 -$388.5 Million -$166.9 Million $104.4 Million
Q3 2023 $0 $0 $0
Q2 2023 -$415.4 Million -$121.5 Million -$122.2 Million
Q1 2023 -$689.4 Million -$125.6 Million -$331.3 Million
Q4 2022 -$488.2 Million -$170.0 Million -$325.5 Million
Q3 2022 -$391.5 Million $0 -$334.9 Million
Q2 2022 -$259.8 Million $0 $181.0 Million
Q1 2022 -$356.7 Million -$120.1 Million -$28.4 Million

View All